Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
15.63
+0.18 (1.17%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.

The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.

It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program.

The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.

Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics, Inc.
Travere Therapeutics logo
CountryUnited States
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees385
CEOEric Dube

Contact Details

Address:
3611 Valley Centre Drive, Suite 300
San Diego, California 92130
United States
Phone888 969 7879
Websitetravere.com

Stock Details

Ticker SymbolTVTX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001438533
CUSIP Number89422G107
ISIN NumberUS89422G1076
Employer ID26-2383102
SIC Code2834

Key Executives

NamePosition
Dr. Eric M. Dube Ph.D.President, Chief Executive Officer and Director
Christopher Cline C.F.A.Chief Financial Officer
Dr. William E. Rote Ph.D.Chief Research Officer
Peter HeermaChief Commercial Officer
Dr. Jula Inrig M.D.Chief Medical Officer
Sandra CalvinSVice President, Corporate Controller and Chief Accounting Officer
Nivi NehraVice President of Corporate Communications and Investor Relations
Elizabeth E. Reed J.D.Chief Legal Officer, General Counsel and Secretary
Angela GiannantonioChief People Officer
Casey LoganChief Business Officer

Latest SEC Filings

DateTypeTitle
Jul 29, 2025SCHEDULE 13G/AFiling
Jun 17, 2025S-8Securities to be offered to employees in employee benefit plans
May 16, 20258-KCurrent Report
May 15, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 14, 2025SCHEDULE 13GFiling
May 5, 2025144Filing
May 5, 2025144Filing